Discover 1,294 paid clinical trials in Chandler, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,294
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
for
Multiple Myeloma (MM)
Location: Gilbert AZ, Louisville KY, Grand Rapids MI, Atlanta GA,
Sponsor: C4 Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07280013
Phase 1, Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
for
Large B-cell Lymphoma, Lymphoma, B-Cell,
Location: Gilbert AZ, Scottsdale AZ, Orange CA, Los Angeles CA,
Sponsor: Lyell Immunopharma, Inc.
Sex: All
Age: 18+
Code: NCT07188558
Phase 3, Recruiting
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
for
Buccal Mucosa Squamous Cell Carcinoma,
Location: Gilbert AZ, Phoenix AZ, Tucson AZ, San Diego CA,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT04333537
Phase 2, Phase 3, Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
for
Acute Myeloid Leukemia (AML)
Location: Gilbert AZ, La Jolla CA, Albuquerque NM, Orange CA,
Sponsor: Kura Oncology, Inc.
Sex: All
Age: 18+
Code: NCT07007312
Phase 3, Recruiting
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
for
Muscle Invasive Bladder Urothelial Carcinoma,
Location: Gilbert AZ, Phoenix AZ, Corona CA, Upland CA, Irvine CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07061964
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER
for
Gastric Adenocarcinoma
Location: Gilbert AZ
Sponsor: Banner Health
Sex: All
Age: 18+
Code: NCT07178808
Phase 2, Recruiting
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
for
Recurrent Non-Muscle Invasive Bladder Carcinoma,
Location: Gilbert AZ, Phoenix AZ, Irvine CA, Orange CA, Reno NV,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT07000084
Phase 3, Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
for
Breast Neoplasms, Triple Negative Breast Neoplasms,
Location: Gilbert AZ, Phoenix AZ, Tucson AZ, Las Vegas NV,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06966700
Phase 3, Recruiting
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
for
Melanoma, Medullary Thyroid Cancer,
Location: Gilbert AZ, Tucson AZ, Seattle WA
Sponsor: University of Arizona
Sex: All
Age: 18 - 70+
Code: NCT06814496
Phase 1, Phase 2, Recruiting
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
for
Pancreatic Cancer, Pancreatic Adenocarcinoma,
Location: Gilbert AZ, Scottsdale AZ, Houston TX, Atlanta GA,
Sponsor: Alpha Tau Medical LTD.
Sex: All
Age: 18 - 70+
Code: NCT06698458
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
for
Metastatic Head-and-neck Squamous-cell Carcinoma,
Location: Gilbert AZ, Tucson AZ, Los Angeles CA, Houston TX,
Sponsor: AVEO Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06064877
Phase 3, Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
for
Hematologic Malignancies, Inherited Disorders of Metabolism,
Location: Gilbert AZ, Phoenix AZ, Tucson AZ, San Diego CA,
Sponsor: Center for International Blood and Marrow Transplant Research
Sex: All
Age: 0+
Code: NCT01351545
Recruiting
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
for
Metastatic Clear Cell Renal Cell Carcinoma,
Location: Gilbert AZ, Tucson AZ, Kingman AZ, Henderson NV,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT04510597
Phase 3, Recruiting
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
for
Cutaneous Melanoma, Stage II
Location: Gilbert AZ, Phoenix AZ, Albuquerque NM, Irvine CA,
Sponsor: Melanoma and Skin Cancer Trials Limited
Sex: All
Age: 18+
Code: NCT03860883
Recruiting
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
for
Androgen Axis Suppression, Prostatectomy, Prostate Cancer
Location: Gilbert AZ, Houston TX, Kansas City KS, Chicago IL,
Sponsor: M.D. Anderson Cancer Center
Sex: Male
Age: 18+
Code: NCT06274047
Phase 3, Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
for
Diffuse Large B-Cell Lymphoma
Location: Gilbert AZ, Phoenix AZ, Tucson AZ, Las Vegas NV,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06717347
Phase 3, Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
for
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC),
Location: Gilbert AZ, West Valley City UT, Aurora CO,
Sponsor: Olema Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06784193
Phase 1, Recruiting
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma